Korro Bio, Inc.
KRRO· Nasdaq
KRROKorro Bio, Inc.
Filed Mar 26, 2024 · 10-K · 86 days after period end · 0000950170-24-036396
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $9.95M |
| Net Income | -$25.43M | $6.19M | -$21.50M | -$10.23M |
| EPS Diluted | — | — | — |
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
| -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Mar 26, 2024 · 86 d after period end
